96 related articles for article (PubMed ID: 23186003)
1. Durable spontaneous regression of lung metastases from renal cell carcinoma after incomplete use of multiple kinase inhibitor sorafenib.
Hegde U; Patel V; Kaloudis E
Int J Urol; 2013 Jun; 20(6):644-5. PubMed ID: 23186003
[No Abstract] [Full Text] [Related]
2. Case of sorafenib-induced thyroid storm.
Haraldsdottir S; Li Q; Villalona-Calero MA; Olencki TE; Kendra K; Ing SW
J Clin Oncol; 2013 Jun; 31(16):e262-4. PubMed ID: 23610115
[No Abstract] [Full Text] [Related]
3. Sorafenib and everolimus in advanced clear cell renal carcinoma: a phase I/II trial of the SCRI Oncology Research Consortium.
Hainsworth JD; Waterhouse DM; Penley WC; Shipley DL; Thompson DS; Webb CD; Anthony Greco F
Cancer Invest; 2013 Jun; 31(5):323-9. PubMed ID: 23614653
[TBL] [Abstract][Full Text] [Related]
4. Spontaneous regression of metastatic papillary renal cell cancer after cessation of treatment with sorafenib.
Grenader T; Rosenbaum E; Zilber S; Bogot N; Shavit L
Clin Genitourin Cancer; 2013 Jun; 11(2):201-3. PubMed ID: 23266054
[No Abstract] [Full Text] [Related]
5. Clinical efficacy and prognostic factors of tumor progression in Japanese patients with advanced renal cell carcinoma treated with sorafenib.
Kondo T; Nakazawa H; Oya M; Kimura G; Fujii Y; Hatano T; Kawata N; Kume H; Morita M; Nakajima K; Ohno Y; Okegawa T; Takahashi S; Wakumoto Y; Horie S; Yamaguchi R; Saito K; Murakami M
Jpn J Clin Oncol; 2015 Mar; 45(3):274-80. PubMed ID: 25420693
[TBL] [Abstract][Full Text] [Related]
6. Multiple squamous cell carcinomas following treatment with sorafenib for renal cell carcinoma.
El Tal AK; Remichofsky CJ; Mehregan DA; Ganger LK
Int J Dermatol; 2013 Dec; 52(12):1538-41. PubMed ID: 23676092
[No Abstract] [Full Text] [Related]
7. Sorafenib induced eruptive melanocytic lesions.
Uhlenhake EE; Watson AC; Aronson P
Dermatol Online J; 2013 May; 19(5):18184. PubMed ID: 24011281
[TBL] [Abstract][Full Text] [Related]
8. Education and imaging. Hepatology: Complete regression of locally advanced hepatocellular carcinoma following Sorafenib monotherapy.
Kumar S
J Gastroenterol Hepatol; 2015 Mar; 30(3):438. PubMed ID: 25707790
[No Abstract] [Full Text] [Related]
9. Sorafenib-Sunitinib Sequence: The Jury Is Out.
Albiges L; Escudier B
Eur Urol; 2015 Nov; 68(5):848-9. PubMed ID: 26184972
[No Abstract] [Full Text] [Related]
10. Delayed onset perforating folliculitis associated with sorafenib.
Batalla A; Menéndez L; Blay P; Curto JR
Australas J Dermatol; 2014 Aug; 55(3):233-5. PubMed ID: 25117168
[No Abstract] [Full Text] [Related]
11. [Metastasized renal cell carcinoma - research subjects needed!].
Aktuelle Urol; 2014 Mar; 45(2):99. PubMed ID: 24700063
[No Abstract] [Full Text] [Related]
12. Choroidal metastasis of renal cell carcinoma: a case report.
Kurashige Y; Otani A; Yoshimura N
Jpn J Ophthalmol; 2010 Jan; 54(1):111-2. PubMed ID: 20151293
[No Abstract] [Full Text] [Related]
13. [Clinical observation of 21 cases of metastatic renal cell carcinoma treated with sorafenib].
Xie XD; Piao Y; Liu ZZ
Zhonghua Zhong Liu Za Zhi; 2009 Sep; 31(9):714-5. PubMed ID: 20021872
[No Abstract] [Full Text] [Related]
14. [First-line therapy of advanced or metastasized renal cell carcinoma: phase III, open, randomized sequence study to examine efficacy and tolerance of sorafenib followed by pazopanib versus pazopanib followed by sorafenib in the first-line treatment of patients with advanced or metastasized renal cell carcinoma (SWITCH-2 - AN 33/11)].
Rexer H;
Urologe A; 2014 May; 53(5):735-8. PubMed ID: 24727992
[No Abstract] [Full Text] [Related]
15. Yellow skin discoloration associated with sorafenib use for treatment of metastatic renal cell carcinoma.
Dasanu CA; Alexandrescu DT; Dutcher J
South Med J; 2007 Mar; 100(3):328-30. PubMed ID: 17396743
[TBL] [Abstract][Full Text] [Related]
16. Long-term response of over ten years with sorafenib monotherapy in metastatic renal cell carcinoma: a case report.
Ueda K; Suekane S; Ogasawara N; Chikui K; Suyama S; Nakiri M; Nishihara K; Matsuo M; Igawa T
J Med Case Rep; 2016 Jun; 10():177. PubMed ID: 27312478
[TBL] [Abstract][Full Text] [Related]
17. Combined Treatment of Tyrosine Kinase Inhibitor-Labeled Gold Nanorod Encapsulated Albumin With Laser Thermal Ablation in a Renal Cell Carcinoma Model.
Callaghan C; Peralta D; Liu J; Mandava SH; Maddox M; Dash S; Tarr MA; Lee BR
J Pharm Sci; 2016 Jan; 105(1):284-92. PubMed ID: 26852860
[TBL] [Abstract][Full Text] [Related]
18. Pneumatosis intestinalis and hepatic portal venous gas in a patient receiving sorafenib.
Kashima T; Ohno Y; Tachibana M
Int J Urol; 2012 Nov; 19(11):1041-2. PubMed ID: 22788573
[No Abstract] [Full Text] [Related]
19. Sorafenib-induced pancreatitis.
Amar S; Wu KJ; Tan WW
Mayo Clin Proc; 2007 Apr; 82(4):521. PubMed ID: 17418082
[No Abstract] [Full Text] [Related]
20. Adjuvant therapy for renal-cell carcinoma: settled for now.
Duensing S; Hohenfellner M
Lancet; 2016 May; 387(10032):1973-4. PubMed ID: 26969091
[No Abstract] [Full Text] [Related]
[Next] [New Search]
